|
Originally published In Press as doi:10.1074/jbc.M007382200 on September 5, 2000
J. Biol. Chem., Vol. 275, Issue 47, 36769-36774, November 24, 2000
Phosphatidylinositol 3-Kinase Activation and Interaction with
Focal Adhesion Kinase in Escherichia coli K1 Invasion of
Human Brain Microvascular Endothelial Cells*
Marpadga A.
Reddy §,
Nemani V.
Prasadarao§¶,
Carol A.
Wass§, and
Kwang Sik
Kim§¶ **
From the § Division of Infectious Diseases, Childrens
Hospital Los Angeles and the Departments of ¶ Pediatrics and
Molecular Microbiology and Immunology, University of Southern
California School of Medicine, Los Angeles, California 90027
Received for publication, August 14, 2000, and in revised form, September 1, 2000
 |
ABSTRACT |
Invasion of brain microvascular endothelial cells
(BMEC) is a prerequisite for successful crossing of the blood-brain
barrier by Escherichia coli K1. We have previously
demonstrated the requirement of cytoskeletal rearrangements and
activation of focal adhesion kinase (FAK) in E. coli K1
invasion of human BMEC (HBMEC). The current study investigated the role
of phosphatidylinositol 3-kinase (PI3K) activation and PI3K interaction
with FAK in E. coli invasion of HBMEC. PI3K inhibitor
LY294002 blocked E. coli K1 invasion of HBMEC in a
dose-dependent manner, whereas an inactive analogue LY303511 had no such effect. In HBMEC, E. coli K1 increased
phosphorylation of Akt, a downstream effector of PI3K, which was
completely blocked by LY294002. In contrast, non-invasive E. coli failed to activate PI3K. Overexpression of PI3K mutants
p85 and catalytically inactive p110 in HBMEC significantly inhibited
both PI3K/Akt activation and E. coli K1 invasion of HBMEC.
Stimulation of HBMEC with E. coli K1 increased PI3K
association with FAK. Furthermore, PI3K/Akt activation was blocked in
HBMEC-overexpressing FAK dominant-negative mutants (FRNK and
Phe397FAK). These results demonstrated the involvement of PI3K
signaling in E. coli K1 invasion of HBMEC and identified a
novel role for PI3K interaction with FAK in the pathogenesis of
E. coli meningitis.
 |
INTRODUCTION |
In neonates, Escherichia coli is the most common
Gram-negative bacterium that causes meningitis, a serious disease
affecting the central nervous system. The most distressing aspect of
neonatal Gram-negative meningitis is high morbidity and mortality
despite advances in antimicrobial chemotherapy and supportive care.
Increased understanding of the pathogenesis and pathophysiology of this disease can lead to improved outcome. Intravascular survival and penetration of the blood-brain barrier by circulating bacteria represent the most critical events in the development of bacterial meningitis (1).
Invasion of brain microvascular endothelial cells
(BMEC)1 is a requirement for
E. coli crossing of the blood-brain barrier, and it involves
attachment of E. coli to BMEC through interaction of
bacterial ligands with corresponding receptors present on BMEC cell
surface (2). Several E. coli determinants (OmpA, IbeA, Ibe
B, and YijP) involved in the invasion of BMEC have been identified (3-6). Receptors on the surface of BMEC for two of these E. coli determinants (OmpA and IbeA) have been characterized
biochemically (7, 8). We have recently demonstrated that E. coli invasion of BMEC occurs via a zipper-like mechanism and
requires cytoskeletal rearrangements in the host cell (9). We have
further characterized in BMEC that E. coli K1 induces
tyrosine phosphorylation of focal adhesion kinase (FAK) and paxillin, a
cytoskeletal protein known to associate with FAK (10). Furthermore,
using FAK dominant-negative mutants we have shown that FAK kinase
activity and its autophosphorylation site tyrosine 397 (Tyr-397)
are critical for E. coli K1 invasion of HBMEC (10). These
results establish that FAK signaling is essential in E. coli
K1 invasion of HBMEC.
FAK is a 125-kDa non-receptor tyrosine kinase and plays an important
role in the assembly of signaling complexes that regulate the
organization of the cytoskeleton and modulate the function of growth
factors. An amino- and a carboxyl-terminal domain of about 400 amino
acids each flank the kinase domain of FAK. The amino-terminal domain
contains an autophosphorylation site (Tyr-397), and the
carboxyl-terminal domain contains focal adhesion targeting sequences
needed for targeting to focal adhesions and binding sites for
intracellular signaling molecules and cytoskeletal proteins (11).
However, the signaling molecules that interact with FAK in E. coli K1 invasion of BMEC have not been identified. The
autophosphorylation site Tyr-397 of FAK has been shown to bind to Src
kinases and phosphatidylinositol 3-kinase (PI3K), and binding to one or
both is required for FAK-mediated functions (12-14). Interestingly, pretreatment of HBMEC with Src kinase-specific inhibitor, PP1, did not
affect E. coli K1 invasion of HBMEC (10). Furthermore, overexpression of Src kinase dominant-negative mutants did not block
E. coli K1 invasion of
HBMEC,2 suggesting an
insignificant role for Src kinases.
In the present study, we examined the role of PI3K in E. coli invasion of HBMEC. PI3K proteins are subdivided into three
major groups, and group I PI3K has been identified as a downstream
effector of both receptor and non-receptor tyrosine kinases (16). Group I PI3K is a heterodimer consisting of a regulatory subunit (p85) and a
110-kDa catalytic subunit (p110). Regulatory subunit p85 contains an
SH3 domain and two SH2 domains that interact with various intracellular
signaling molecules. Interaction of the SH2 domains of p85 subunit with
phosphotyrosine residues on tyrosine kinases, including Src and FAK,
results in PI3K activation. PI3K catalytic subunit p110 phosphorylates
the D-3 position of the inositide ring of
phosphatidylinositol, and its derivatives form the second messenger
phosphatidylinositol 3,4,5-trisphosphate. Phosphatidylinositol
3,4,5-trisphosphate binding to pleckstrin homology (PH) domains of
various cellular and cytoskeletal proteins mediates membrane
recruitment of several kinases including, Akt (protein kinase B), PDK1,
and PDK2. Akt is then activated by sequential phosphorylation on
Thr-308 and Ser-473 by phosphoinositide-dependent protein
kinases PDK1 and PDK2, respectively (17). PI3K signaling has been
implicated in a variety of cellular processes, including survival,
proliferation, migration, metabolic changes (18 and 19) and
Listeria monocytogenes invasion of epithelial cells (20). PI3K has been shown to act downstream of FAK in cell migration and
survival (21-23). In this paper, we report the activation of PI3K/Akt
signaling in E. coli K1 invasion of HBMECs and demonstrate that PI3K interaction with FAK is required for the activation of
PI3K/Akt signaling in this process.
 |
EXPERIMENTAL PROCEDURES |
Materials--
Monoclonal antibodies to FAK and p85 were
purchased from Transduction Laboratories (Lexington, KY). Polyclonal
Akt antibody, which recognizes the carboxyl-terminal end, and
horseradish peroxidase-conjugated anti-goat antibody were from Santa
Cruz Biotechnologies (Santa Cruz, CA). Phospho-Akt antibody, which
recognizes the activated form of Akt, was purchased from New England
BioLabs (Beverly, MA). Protein A-agarose was from Roche Molecular
Biochemicals. M2 monoclonal antibody that recognizes FLAG epitope was
purchased from Sigma Chemical Co. (St. Louis, MO). PI3K inhibitor
LY294002 was purchased from Calbiochem (San Diego, CA), and its
inactive analogue LY303511 was a gift from Dr. Chris Vlahos (Eli Lilly and Co., Indianapolis, IN). Horseradish peroxidase-conjugated anti-mouse and anti-rabbit secondary antibodies were obtained from
Bio-Rad Labs (Hercules, CA). Super Signal chemiluminescence reagent and
bicinchoninic acid protein assay kit were from Pierce Chemical Co.
(Rockford, IL). LipofectAMINE was from Life Technologies, Inc.
(Bethesda, MD). All other chemicals were obtained from Sigma. PI3K mutant p110 K, a kinase-negative catalytic subunit of p110, and
p85, defective in interaction with p110, were described previously (24, 25). Mammalian expression vector pcDNA3-expressing
kinase-negative p110 and p85 mutants with the FLAG epitope tag were
kindly provided by L. C. Cantley (Harvard Medical School, Boston,
MA). Expression vectors for FAK mutants lacking the autophosphorylation
site (Phe397FAK) and amino-terminal domain (FRNK) were described
previously (26, 27). Strain E44 is a rifampin-resistant mutant of
E. coli K1 strain RS218 (serotype 018:K1:H7) isolated from
the cerebrospinal fluid of a neonate with meningitis and has been shown
to invade brain microvascular endothelial cells (2). E. coli
HB101 is a non-invasive laboratory strain (3).
Endothelial Cell Culture and Transfections--
Human brain
microvascular endothelial cells (HBMEC) were isolated and cultured as
described previously (28). HBMEC cultures were routinely grown on rat
tail collagen-coated dishes in RPMI medium containing 10%
heat-inactivated fetal bovine serum, 10% Nu-Serum, 2 mM
glutamine, 1 mM pyruvate, penicillin (100 units/ml), streptomycin (100 µg/ml), essential amino acids, and vitamins. HBMECs
were transfected with mammalian expression vectors coding for PI3K
mutants using LipofectAMINE as described previously (10). Briefly,
DNA-LipofectAMINE complex in RPMI was added to 50% confluent HBMEC
monolayers. After 6 h of incubation at 37 °C, cells were washed
with RPMI and complete medium was added. Three days after the
transfection, HBMEC were transferred to medium containing an antibiotic
G418 (400 µg/ml) for 2-3 weeks, and antibiotic-resistant colonies
were pooled for further analysis. HBMEC-expressing FAK mutant Phe397FAK
was maintained in medium containing G418 (400 µg/ml) and
FRNK-expressing cells in the presence of hygromycin (100 µg/ml) as
described previously (10).
E. coli Invasion Assays--
E. coli invasion of
HBMEC was performed as described earlier (3). Briefly, confluent
endothelial cells in 24-well plates were incubated with 1 × 107 E. coli (multiplicity of infection of 100)
in experimental medium (1:1 mixture of M199:Ham's F-12 containing 5%
heat-inactivated fetal bovine serum) for 90 min at 37 °C. The
monolayers were washed with RPMI and then incubated in
experimental medium containing gentamicin (100 µg/ml) for 1 h to
kill extracellular bacteria. The monolayers were washed again and lysed
with 0.5% Triton X-100. The released intracellular bacteria were
enumerated by plating on sheep blood agar plates. In some experiments
HBMEC were pretreated with various inhibitors for 30 min prior to
stimulation with bacteria. Results were expressed as relative invasion
(percentage of invasion in comparison to that of untreated HBMEC or
HBMEC transfected with control vectors).
Cell Lysates and Immunoprecipitation--
Preparations of cell
lysates and immunoprecipitation were performed as described previously
(10). Confluent monolayers of HBMEC were stimulated with E. coli resuspended in experimental medium at a multiplicity of
infection of 100 for the indicated periods of time, and the monolayers
were washed with cold phosphate-buffered saline containing 1 mM sodium orthovanadate. Cells were lysed in modified
radioimmune precipitation buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 1%
Triton X-100, 0.5% deoxycholate, 0.1% SDS, 1 mM sodium
orthovanadate, 50 mM NaF, 10 mM sodium
pyrophosphate, 25 mM -glycerophosphate, 1 mM
phenylmethylsulfonyl fluoride, and 10 µg/ml each of leupeptin and
aprotinin), at 4 °C for 20 min. The cell lysates were centrifuged at
16,000 × g for 20 min at 4 °C. The
supernatant was collected, and protein content was determined using the
bicinchoninic acid kit. For immunoprecipitation, 300-500 µg of
protein was incubated with appropriate antibody overnight at 4 °C
and incubated for 1 h with Protein A-agarose. The immune complexes
were washed four times with radioimmune precipitation buffer without
deoxycholate, and the proteins from immune complexes were eluted in SDS
sample buffer for further analysis by Western blotting.
Western Blotting--
Proteins in immune complexes or total cell
lysates were electrophoresed on 10% SDS-polyacrylamide electrophoresis
gels and transferred to polyvinylidene difluoride membranes. The blots were blocked with TBST (25 mM Tris, pH 7.4, 150 mM NaCl, and 0.1% Tween 20) containing 3% bovine serum
albumin for 2 h at room temperature and incubated with appropriate
primary antibody overnight at 4 °C or for 2 h at room
temperature. Then, the blots were washed with TBST and incubated with
horseradish peroxidase-conjugated secondary antibody for 1 h at
room temperature. Subsequently, the blots were washed with TBST and
developed with Super Signal chemiluminescence reagent. The blots were
exposed to x-ray film to visualize the proteins. The protein bands on
autoradiograms were scanned by using a GS-700 imaging densitometer, and
the intensity of bands was analyzed using Quantitation One software
(Bio-Rad).
 |
RESULTS |
Inhibition of E. coli Invasion by PI3K Inhibitors--
We have
previously shown that the invasion of E. coli K1 induces
activation of non-receptor tyrosine kinase FAK and its
autophosphorylation site Tyr-397 is essential for E. coli
invasion of HBMEC (10). Tyrosine 397 of FAK interacts with various
intracellular signaling molecules, including Src kinases and PI3K, for
FAK promoted biological effects. However, our earlier studies have
demonstrated a minimal or no role for Src kinases in E. coli
invasion of HBMEC.2 Hence, the involvement of PI3K in
E. coli invasion of HBMEC was studied using a PI3K-specific
inhibitor LY294002. HBMEC were pretreated with either experimental
medium (Control) or experimental medium containing various
concentrations of LY294002 (1-50 µM) for 30 min. Then,
E. coli invasion assays were performed on these cells using
invasive E. coli K1 strain E44, and the results were
expressed as a percentage of the control. Fig.
1 shows that LY294002 inhibited E. coli K1 invasion of HBMEC in a dose-dependent manner
with an IC50 of 5 µM (13,734 ± 1,000 cfu/well without inhibitor versus 834 ± 85 cfu/well
with 50 µM LY294002, p < 0.001). Binding
of E. coli to HBMEC was not affected by LY294002
pretreatment, and LY294002 was not toxic to HBMEC even at 100 µM as determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium assay (data not shown). To confirm that the observed inhibition was specific to
LY294002, E. coli invasion assays were also performed with LY303511, which is an inactive analogue of LY294002. The results (Fig.
1) showed that, even at 50 µM concentration, LY303511 had very little effect on E. coli K1 invasion of HBMEC. These
results suggest the PI3K activity is required for E. coli K1
invasion of HBMEC.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 1.
PI3K inhibitors block E. coli
K1 invasion of HBMEC. E. coli invasion assays
were performed with HBMEC pretreated with experimental medium (control)
or experimental medium containing PI3K inhibitor LY294002 or its
inactive analogue LY303511. The results were expressed as percentage of
control HBMEC (13,734 ± 1,462 cfu/well). The data represent five
independent experiments performed in triplicate. Error bars
indicate standard deviation.
|
|
Activation of PI3K by Invasive E. coli K1 in
HBMEC--
Stimulation of PI3K results in activation of a Ser/Thr
kinase Akt (protein kinase B). Products generated by PI3K recruit Akt to the membrane, where a Ser/Thr kinase PDK1 phosphorylates Thr-308 followed by Ser-473 by PDK2, resulting in the activation of Akt. Activation of Akt is sensitive to PI3K inhibitors, and the
phosphorylated Akt can be detected using phosphospecific Akt
antibodies. We, therefore, used Akt activation as a parameter for
determining PI3K activation in HBMEC by E. coli. To test the
activation of PI3K, HBMEC were stimulated with invasive E. coli K1 strain E44 and non-invasive E. coli strain
HB101. As a positive control, HBMECs were stimulated with epidermal
growth factor (EGF) in the same experiment. Then, the HBMEC monolayers
were lysed and cell lysates were immunoprecipitated with anti-Akt
antibody that recognizes both phosphorylated and non-phosphorylated
forms. Immunoprecipitates were subjected to immunoblotting with either
phosphospecific Akt antibody or the Akt antibody and the phospho-Akt
bands were quantitated using image analysis software. The results are
shown in Fig. 2A. As expected,
EGF treatment of HBMEC robustly increased Akt phosphorylation (10-fold
increase in lane 3, compared with control cells in
lane 1). In HBMEC stimulated with E44, Akt phosphorylation
increased significantly (3-fold, lane 2) compared with
control cells (lane 1). In contrast, non-invasive E. coli strain HB101 failed to increase phosphorylation of Akt
(lane 4). Next, we examined the effect of PI3K inhibitor
LY294002 on E. coli-stimulated Akt phosphorylation in HBMEC.
Both control and HBMEC pretreated with LY294002 (25 µM)
were stimulated with E44, and Akt was immunoprecipitated from the cell
lysates. Immunoblotting with phospho-Akt antibodies revealed that
E. coli K1 stimulated phosphorylation of Akt by 2.8-fold (Fig. 2C, lane 2) compared with control cells
(Fig. 2C, lane 1), and it was abolished by 25 µM LY294002 (Fig. 2C, lane 4), a
concentration at which E. coli K1 invasion was effectively
inhibited. These results clearly demonstrate that Akt activation is
specific to invasive E. coli K1 and is
PI3K-dependent.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 2.
Activation of PI3K in HBMEC stimulated with
E. coli. HBMEC were treated with indicated
agents, and cell lysates were prepared as described under
"Experimental Procedures." The lysates were immunoprecipitated with
Akt antibody, and the immunoprecipitates were immunoblotted with either
phospho-Akt antibody, which recognizes the activated form of Akt
(pAkt), or Akt antibody (AKT). The density of
phospho-Akt bands on autoradiographs was quantitated using imaging
densitometer as described under "Experimental Procedures." Where
indicated, HBMEC were pretreated with PI3K inhibitor LY294002
(LY). Data in B and D represent the
average of three independent experiments. Error bars
indicate standard deviation. A, immunoblotting of the Akt
immunoprecipitates with anti-phospho-Akt or anti-Akt antibody.
Immunoprecipitates were obtained from HBMEC treated with experimental
medium (C) or medium containing E44, HB101, or 100 ng/ml
epidermal growth factor (EGF), for 10 min. B,
phospho-Akt bands in A were quantitated, and the results are
expressed as -fold increase of control HBMEC. C, Akt
immunoprecipitates obtained from control HBMEC or stimulated with E44,
in the absence ( ) or presence (+) of PI3K inhibitor LY294002 were
immunoblotted with indicated antibodies. D, quantitation of
phospho-Akt bands in C.
|
|
Dominant-Negative Mutants of PI3K Blocked the E. coli K1 Invasion
of HBMEC--
To further demonstrate the role of PI3K in E. coli invasion, HBMEC were transfected with dominant-negative
mutants of either p85 ( p85) or p110 (p110 K) subunits of PI3K. The
cDNAs of both mutants were cloned under the control of
cytomegalovirus promoter with an amino-terminal FLAG epitope tag in the
eucaryotic expression vector pcDNA3, which also confers G418
resistance. The p85 mutant contains a defective iSH2 region, fails
to bind to PI3K catalytic subunit p110, and dominantly inhibits the
activation of PI3K by titrating out the signaling molecules that
interact with PI3K. Whereas, p110 K is a kinase inactive mutant, has
a CAAX motif, and is constitutively translocated to the
membrane. HBMEC transfected with the expression vector pcDNA3 was
used as a control. HBMEC colonies resistant to G418 were pooled and
used in further experiments. Lysates from transfected cells were
immunoprecipitated with either p85 antibody or p110 antibody. Analysis
of immunoprecipitates by immunoblotting with FLAG antibody (M2) showed
that both p110 and p85 are expressed only in HBMEC transfected with
appropriate vector but not in cells transfected with pcDNA3 (Fig.
3A). HBMEC transfected with
pcDNA3 or PI3K mutants were used in E. coli invasion assays with E44, and the results of E. coli K1 invasion in
HBMEC-expressing PI3K mutants were compared with those in cells
expressing pcDNA3. As shown in Fig. 3B, E. coli K1 invasion of HBMEC was blocked by 85% and 50%,
respectively, in cells expressing p110 K and p85 (12,400 ± 1,172 cfu/well with pcDNA3 versus 1,860 ± 168 cfu/well and 6,300 ± 651 cfu/well in HBMEC transfected with
p110 and p85, respectively, p < 0.002). These
results clearly support that PI3K is involved in E. coli K1
invasion of HBMEC.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 3.
Overexpression of PI3K mutants blocked
E. coli K1 invasion of HBMEC. A,
expression of p85 and p110 K mutants in HBMEC: Cell lysates from
HBMEC, transfected with FLAG epitope-tagged PI3K mutants p85 or
p110 K, were immunoprecipitated with p85 or p110 antibody,
respectively. Immunoprecipitates were then immunoblotted with indicated
antibodies. B, overexpression of PI3K mutants blocked
E. coli K1 invasion of HBMEC: HBMEC, transfected with
pcDNA3, or p85, or p110 K, were used in E. coli
invasion assays. The results are expressed as percentage of HBMEC
transfected with pcDNA3. The results represent mean of five
independent experiments performed in triplicate. Error bars
indicate standard deviation.
|
|
PI3K Mutants Abolished E. coli K1 Activation of PI3K in
HBMEC--
Next, we tested whether PI3K activation is inhibited in
HBMEC-expressing PI3K mutants. The HBMEC cells transfected with
pcDNA3, p85, or p110 were stimulated with E44 for 10 min, and
the cell lysates were immunoprecipitated with Akt antibody.
Immunoprecipitates were divided into two aliquots and subjected to
immunoblotting with either phospho-Akt antibody or non-phospho-Akt
antibody. The levels of phospho-Akt were determined, and the results
are shown in Fig. 4, A and
B. E44 stimulated Akt activation by 3-fold in cells
transfected with pcDNA3 (Fig. 4, lane 2), whereas Akt activation was inhibited in HBMEC transfected with PI3K mutants p85
(Fig. 4, lane 5) or p110 K (Fig. 4, lane 8).
Activation of Akt by EGF was also inhibited in cells expressing both
PI3K mutants compared with HBMEC transfected with pcDNA3 ((Fig. 4,
lanes 3, 6, and 9). These results
demonstrated that PI3K activation by E. coli K1 is inhibited
in HBMEC-expressing dominant-negative mutants of PI3K. Taken together,
these findings indicate that PI3K activation is required for E. coli K1 invasion of HBMEC.

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 4.
Inhibition of Akt activation in
HBMEC-overexpressing PI3K mutants. A, HBMEC transfected
with pcDNA3 or p85 or p110 K were either left alone
(C) or stimulated with either E44 or epidermal growth factor
(EGF) for 10 min, and the cell lysates were
immunoprecipitated with anti-Akt antibody. Immunoprecipitates were
immunoblotted with either anti-phospho-Akt antibody or anti-Akt
antibody. B, the intensity of phospho-Akt bands was
determined as described under "Experimental Procedures." The
phospho-Akt levels were expressed as compared with HBMEC transfectants
treated with experimental medium (-fold increase of control). Data
represent average of three independent experiments. Error
bars indicate standard deviation.
|
|
PI3K Interaction with FAK in HBMEC Stimulated with E. coli--
The regulatory subunit p85 interacts with the
autophosphorylation site (Tyr-397) of FAK. Because Tyr-397 is critical
for FAK signaling in E. coli K1 invasion of HBMEC (10), we
examined whether p85 interacts with FAK. The cell lysates from HBMEC
stimulated with E44 were immunoprecipitated with FAK antibody, and
immunoprecipitates were analyzed by immunoblotting with p85 antibody.
Immunoprecipitates were also immunoblotted with FAK antibody to verify
the presence of equal amounts of FAK protein levels in each
immunoprecipitate. As shown in Fig. 5,
p85 association with FAK was seen in control HBMEC (lane 1)
and this association was increased in HBMEC stimulated with E44 for 5 min (lane 2), 10 min (lane 3), and 30 min
(lane 4). Immunoblotting with FAK antibody showed that
immunoprecipitates contained equal amounts of FAK in all the samples.
These results demonstrated that PI3K association with FAK is increased
in cells stimulated with E. coli K1, which may be required
for HBMEC invasion.

View larger version (44K):
[in this window]
[in a new window]
|
Fig. 5.
PI3K association with FAK in HBMEC.
A, HBMEC were either left alone (C) or treated
with E44 for various periods of time (5, 10, and 30 min), and cell
lysates were immunoprecipitated with FAK antibody. The FAK
immunoprecipitates were immunoblotted with either p85 or with FAK
antibody. The numbers above the lanes indicate the time in
minutes. Similar results were obtained in another experiment.
|
|
Inhibition of PI3K Activation by FAK Dominant-Negative
Mutants--
E. coli K1 invasion of HBMEC is inhibited in
cells overexpressing FAK dominant-negative mutants FRNK and
autophosphorylation mutant Phe397FAK (10). Having demonstrated the
interaction of PI3K with FAK in HBMEC stimulated with E. coli K1, we next investigated if PI3K activation would be blocked
by FAK dominant-negative mutants. HBMEC transfected with pcDNA3,
FRNK, and Phe397FAK were stimulated with E44, and cell lysates were
immunoprecipitated with Akt antibody. Analysis of immunoprecipitates
with phospho-Akt antibody revealed that E. coli-stimulated
Akt activation was completely abolished in HBMEC transfected with
Phe397FAK and partially abolished in cells expressing FRNK (Fig.
6). Thus, PI3K activation is inhibited in
cells where FAK activation is blocked by dominant-negative mutants.

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 6.
Inhibition of Akt activation in
HBMEC-overexpressing FAK mutants. HBMEC transfected with
pcDNA3 or FRNK or Phe397FAK were either left alone ( ) or
stimulated with E. coli K1 E44 (+) for 10 min, and the cell
lysates were immunoprecipitated with anti-Akt antibody. The
immunoprecipitates were then immunoblotted with either anti-phospho-Akt
antibody or anti-Akt antibody as indicated under "Experimental
Procedures." Similar results were obtained in another
experiment.
|
|
 |
DISCUSSION |
Bacterial entry of mammalian cells involves a complex interplay of
bacterial determinants with host cell receptors and is associated with
activation of specific signaling pathways (2). Our previous studies
have demonstrated that FAK plays a central role in E. coli
K1 invasion of HBMEC (10). However, the mechanisms of FAK activation
and signaling molecules that interact with FAK in this process have
been not identified. In this paper, we report that PI3K activation and
its interaction with FAK are required for E. coli K1
invasion of HBMEC. This was shown by blockade of both PI3K activation
and E. coli invasion of HBMEC with specific PI3K inhibitor
(LY294002) as well as using dominant-negative mutants of PI3K ( p85
and p110 K) and FAK (FRNK and FAKY397F).
The regulatory subunit p85 of PI3K contains an amino-terminal SH3
domain, a breakpoint cluster homology domain and two SH2 domains. These
domains allow p85 to simultaneously interact with multiple
intracellular signaling molecules (16). Thus, PI3K can recruit a
variety of signaling molecules to the site of bacterial entry. There
are several phosphoinositide binding proteins, which can be potential
downstream effectors of PI3K, that can participate at several steps in
E. coli invasion of HBMEC, including cytoskeletal rearrangements or the endosome formation. One of them is the Rho family of GTP binding proteins that regulates actin rearrangement. Rho
family members cycle between the inactive GDP binding form and the
active GTP binding form. Guanine nucleotide exchange factors (GEF) and
GTPases regulate the cycling of Rho-like GTPases. GEFs mediate
conversion of inactive GDP-bound form to active GTP-bound form. PI3K
products can bind to pleckstrin homology domains in GEF and target them
to plasma membrane to activate Rho family of GTPases (29). We showed
that the E. coli K1 mutant lacking cytotoxic necrotizing
factor-1 failed to invade HBMEC (30), suggesting the involvement of Rho
GTPases. Cytotoxic necrotizing factor-1 is known to activate Rho
GTPases in mammalian cells (31, 32). PI3K may be required for the
regulation of Rho-like GTPases in HBMEC. Many cytoskeletal proteins
involved in the regulation of actin polymerization bind to
phosphoinositides through their pleckstrin homology (PH) domains,
e.g. profilin and capping proteins bind to monomeric actin
and prevent its polymerization. Binding of phosphoinositides to the PH
domains of these proteins releases actin and promotes polymerization
(33). Phosphoinositide-induced changes in the conformation of another
cytoskeletal protein vinculin may also play a role in focal adhesion
assembly by promoting cross-linking of talin to actin. Another
mechanism for the PI3K involvement could be the activation of Akt, a
Ser/Thr kinase, which is recruited to plasma membrane by binding to
phosphoinositides through its PH domain. Evidence exists for the
involvement of Akt in actin reorganization and migration of
microvascular endothelial cells (34). Upon entry into HBMEC, E. coli have been shown to be located in vacuoles and cross the HBMEC
by transcytosis (9). This is another level where PI3K may be involved,
because PI3K has been shown to participate in the recruitment of early
endosome proteins as well as movement of the endosomes along the
microtubules (35, 36). Studies are in progress to examine the role of
PI3K in cytoskeleton rearrangements and trafficking of E. coli-containing vacuoles in HBMEC.
Our recent results have demonstrated the cytoskeletal changes in HBMEC
at the site of bacterial entry (9). These sites were similar to focal
adhesions that are intracellularly associated with protein complexes
consisting of cytoskeletal proteins and tyrosine kinase FAK (37). The
role of FAK has been studied in many cellular responses associated with
cytoskeleton rearrangement, including adhesion and migration (38).
However, the mechanism of FAK activation and the proteins recruited by
FAK in E. coli invasion of HBMEC have not been identified.
The present study identified that PI3K interacts with FAK in HBMEC and
its interaction is enhanced in HBMEC stimulated with E. coli
K1, suggesting that FAK recruits PI3K to the site of bacterial entry.
PI3K activation was abolished by FAK dominant-negative mutants FRNK and
FAKY397F, indicating that FAK may be upstream of PI3K in E. coli K1 invasion of HBMEC. In contrast, tyrosine phosphorylation
of FAK was not affected by PI3K inhibitors (data not shown), providing
further support for this mechanism.
Several E. coli K1 determinants involved in the HBMEC
invasion have been identified, and some of these bacterial proteins induced cytoskeleton rearrangements in HBMEC (2). However, at present,
the identity of E. coli K1 structures responsible for the
activation of FAK and/or PI3K and the mechanism of activation in HBMEC
are not yet defined. Of interest, uropathogenic E. coli invasion of bladder epithelial cells was found to require host actin
reorganization, FAK phosphorylation at Tyr-397 and PI3K activation, but
not activation of Src-family tyrosine kinases (39). These events were
mediated by FimH and correlated with the formation of complexes between
FAK and PI3K. Thus, our findings of PI3K activation and PI3K/FAK
interactions reported here with E. coli K1 invasion of HBMEC
are similar to those observed with type 1 pilus E. coli
invasion of uroepithelial cells.
We have previously demonstrated that other meningitis-causing bacteria,
e.g. group B streptococcus (40), Citrobacter
freundii (41), and L. monocytogenes (42), are able to
invade HBMEC. PI3K involvement has been demonstrated in L. monocytogenes invasion of epithelial cells. However, PI3K
involvement is independent of FAK in L. monocytogenes
invasion of epithelial cells (15). In contrast, our findings indicate
the requirement of PI3K interaction with FAK in E. coli K1
invasion of HBMEC. Thus, the mechanism of E. coli K1
invasion of HBMEC is strikingly different from that of L. monocytogenes. This may reflect the differences in cell types,
bacterial ligands, and mechanisms of diseases. It would be interesting
to see whether PI3K/FAK interactions are also involved in the invasion
of HBMEC by other meningitis-causing bacteria.
 |
ACKNOWLEDGEMENTS |
We thank Dr. M. F. Stins for help with
culturing human brain microvascular endothelial cells.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grants R01-NS-26310, AI-47225, and HL-61951 (to K. S. K.) and
R29-AI-40567 (to N. V. P.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Current address: Division of Diabetes, Endocrinology and
Metabolism, Beckman Research Inst. City of Hope National Medical Center, Duarte, CA 91010.
**
To whom correspondence should be addressed: Pediatric Infectious
Diseases Division, Johns Hopkins University School of Medicine, 600 North Wolfe St., Park 256, Baltimore, MD 21287. Tel.:
410-614-3917; Fax: 410-614-1491; E-mail: kwangkim@jhmi.edu.
Published, JBC Papers in Press, September 5, 2000, DOI 10.1074/jbc.M007382200
2
M. A. Reddy, N. V. Prasadarao, and
K. S. Kim, unpublished results.
 |
ABBREVIATIONS |
The abbreviations used are:
BMEC, brain
microvascular endothelial cells;
HBMEC, human BMEC;
FAK, focal adhesion
kinase;
FRNK, FAK dominant-negative mutant;
PI3K, phosphatidylinositol
3-kinase;
PH, pleckstrin homology;
Akt, protein kinase B;
cfu, colony-forming units;
EGF, epidermal growth factor;
E44, spontaneous
rifampin-resistant mutant of strain RS218 (018:K1:H7);
GEF, guanine nucleotide exchange factor.
 |
REFERENCES |
| 1.
|
Leib, L. S.,
and Tauber, M. G.
(1999)
Infect. Dis. Clin. North Am.
13,
527-548
|
| 2.
|
Kim, K. S.
(2000)
Subcell. Biochem.
33,
47-59
|
| 3.
|
Prasadarao, N. V.,
Wass, C. A.,
Weiser, J. N.,
Stins, M. F.,
Huang, S. H.,
and Kim, K. S.
(1996)
Infect. Immun.
64,
146-153
|
| 4.
|
Huang, S. H.,
Wass, C. A.,
Fu, Q.,
Prasadarao, N. V.,
Stins, M. F.,
and Kim, K. S.
(1995)
Infect. Immun.
63,
4470-4475
|
| 5.
|
Huang, S. H.,
Chen, Y. H.,
Fu, Q.,
Stins, M.,
Wang, Y.,
Wass, C.,
and Kim, K. S.
(1999)
Infect. Immun.
67,
2103-2109
|
| 6.
|
Wang, Y.,
Huang, S. H.,
Wass, C. A.,
Stins, M. F.,
and Kim, K. S.
(1999)
Infect. Immun.
67,
4751-4756
|
| 7.
|
Prasadarao, N. V.,
Wass, C. A.,
and Kim, K. S.
(1996)
Infect. Immun.
64,
154-160
|
| 8.
|
Prasadarao, N. V.,
Wass, C. A.,
Huang, S. H.,
and Kim, K. S.
(1999)
Infect. Immun.
67,
1131-1138
|
| 9.
|
Prasadarao, N. V.,
Wass, C. A.,
Stins, M. F.,
Shimada, H.,
and Kim, K. S.
(1999)
Infect. Immun.
67,
5775-5783
|
| 10.
|
Reddy, M. A.,
Wass, C. A.,
Kim, K. S.,
Schlaepfer, D. D.,
and Prasadarao, N. V.
(2000)
Infect. Immun.
68,
6423-6430
|
| 11.
|
Schlaepfer, D. D.,
Hauck, C. R.,
and Sieg, D. J.
(1999)
Prog. Biophys. Mol. Biol.
71,
435-478
|
| 12.
|
Xing, Z.,
Chen, H.-C.,
Nowlen, J. K.,
Taylor, S.,
Shalloway, D.,
and Guan, J.-L.
(1994)
Mol. Biol. Cell
5,
413-442
|
| 13.
|
Cobb, B. S.,
Schaller, M. D.,
Leu, T.-H.,
and Parsons, J. T.
(1994)
Mol. Cell. Biol.
14,
147-155
|
| 14.
|
Chen, H.-C.,
and Guan, J.-L.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
10148-10152
|
| 15.
|
Ireton, K.,
Payrastre, B.,
and Cossart, P.
(1999)
J. Biol. Chem.
274,
17025-17032
|
| 16.
|
Wymann, M. P.,
and Pirola, L.
(1998)
Biochim. Biophys. Acta
1436,
127-150
|
| 17.
|
Downward, J.
(1998)
Science
279,
673-674
|
| 18.
|
Martin, J. F.
(1998)
Ann. Rev. Cell. Dev. Biol.
14,
231-264
|
| 19.
|
Ramesh, L. E.,
and Cantley, L. C.
(1999)
J. Biol. Chem.
274,
8347-8350
|
| 20.
|
Ireton, K.,
Payrastre, B.,
Chap, H.,
Ogawa, W.,
Sakaue, H.,
Kasuga, M.,
and Cossart, P.
(1997)
Science
274,
780-782
|
| 21.
|
Reiske, H. R.,
Kao, S.-C.,
Cary, L. A.,
Guan, J.-L.,
Lai, J.-F.,
and Chen, H.-C.
(1999)
J. Biol. Chem.
274,
12361-12366
|
| 22.
|
Sonoda, Y.,
Watanabe, S.,
Matsumoto, Y.,
Aizu-Yokota, E.,
and Kasahara, T.
(1999)
J. Biol. Chem.
274,
10566-10570
|
| 23.
|
Chan, P.-C.,
Lai, J.-F.,
Cheng, C.-H.,
Tang, M.-J.,
Cjiu, C.-C.,
and Chen, H.-C.
(1999)
J. Biol. Chem.
274,
26901-26906
|
| 24.
|
Hara, K.,
Yonezawa, K.,
Sakaue, H.,
Ando, A.,
Kotani, K.,
Kitamura, T.,
Kitamura, Y.,
Ueda, H.,
Stephens, L.,
Jackson, T. R.,
Hawkins, P. T.,
Dhand, R.,
Clark, A. E.,
Holman, G. D.,
Waterfield, M. D.,
and Kasuga, M.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
7415-7419
|
| 25.
|
Rodriguez-Viciana, P.,
Warne, P. H.,
Vanhaesebroeck, B.,
Waterfield, M. D.,
and Downward, J.
(1996)
EMBO J.
15,
2442-2451
|
| 26.
|
Schlaepfer, D. D.,
and Hunter, T.
(1997)
J. Biol. Chem.
272,
13189-13195
|
| 27.
|
Sieg, D. J.,
Hauck, C. R.,
and Schlaepfer, D. D.
(1999)
J. Cell Sci.
112,
2677-2691
|
| 28.
|
Stins, M. F.,
Gilles, F.,
and Kim, K. S.
(1997)
J. Neuroimmunol.
76,
81-90
|
| 29.
|
Carpenter, C. L.,
Tolias, K. F.,
Couvillion, A. C.,
and Hartwig, J. H.
(1997)
Adv. Enz. Regul.
37,
377-390
|
| 30.
| Wang, Y., Wass, C., and Kim, K. S. (2000) in Abstracts of
the 100th American Society for Microbiology General Meeting, Los
Angeles, May 21-25; Abstr. B108, p. 65
|
| 31.
|
Schmidt, G.,
Sehr, P.,
Wilm, M.,
Selzer, J.,
Mann, M.,
and Aktories, K.
(1997)
Nature
387,
725-729
|
| 32.
|
Flatau, G.,
Lemichez, E.,
Gauthier, M.,
Chardin, P.,
Fiorentini, C.,
and Boquet, P.
(1997)
Nature
387,
729-733
|
| 33.
|
Schmidt, A.,
and Hall, M. N.
(1998)
Ann. Rev. Cell. Dev. Biol.
14,
305-338
|
| 34.
|
Morales-Ruiz, M.,
Fulton, D.,
Sowa, G.,
Languino, L. R.,
Fujio, Y.,
and Wlash, K.
(2000)
Circ. Res.
86,
892-896
|
| 35.
|
Nielsen, E.,
Severin, F.,
Backer, J. M.,
Hyman, A. A.,
and Zerial, M.
(1999)
Nat. Cell Biol.
1,
376-382
|
| 36.
|
Gaullier, J. M.,
Simonsen, A.,
D'Arrigo, A.,
Bremnes, B.,
Stenmark, H.,
and Aasland, R.
(1998)
Nature
394,
432-433
|
| 37.
|
Brigitte, M. J.,
Bubeck, P.,
Giegl, K.,
Kroemker, M.,
Moschner, J.,
Rothkegel, M.,
Rudiger, M.,
Schluter, K.,
Stanke, G.,
and Winkler, J.
(1995)
Ann. Rev. Cell. Dev. Biol.
11,
379-416
|
| 38.
|
Guan, J.-L.,
and Chen, H.-C.
(1996)
Int. Rev. Cytol.
168,
81-108
|
| 39.
|
Martinez, J. J.,
Mulvey, M. A.,
Schilling, J. D.,
Pinkner, J. S.,
and Hultgren, S. J.
(2000)
EMBO J.
19,
2803-2812
|
| 40.
|
Nizet, V.,
Kim, K. S.,
Stins, M.,
Jonas, M.,
Chi, E. Y.,
Nguyen, D.,
and Rubens, C. E.
(1997)
Infect. Immun.
65,
5074-5081
|
| 41.
|
Badger, J. L.,
Stins, M. F.,
and Kim, K. S.
(1999)
Infect. Immun.
67,
4208-4215
|
| 42.
|
Greiffenberg, L.,
Goebel, W.,
Kim, K. S.,
Weiglein, I.,
Rubert, A.,
Engelbrecht, R.,
Stins, M.,
and Kuhn, M.
(1998)
Infect. Immun.
66,
5260-5267
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. Nerlich, M. Rohde, S. R. Talay, H. Genth, I. Just, and G. S. Chhatwal
Invasion of Endothelial Cells by Tissue-invasive M3 Type Group A Streptococci Requires Src Kinase and Activation of Rac1 by a Phosphatidylinositol 3-Kinase-independent Mechanism
J. Biol. Chem.,
July 24, 2009;
284(30):
20319 - 20328.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Agarwal and S. Hammerschmidt
Cdc42 and the Phosphatidylinositol 3-Kinase-Akt Pathway Are Essential for PspC-mediated Internalization of Pneumococci by Respiratory Epithelial Cells
J. Biol. Chem.,
July 17, 2009;
284(29):
19427 - 19436.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Ishibe, J. E. Haydu, A. Togawa, A. Marlier, and L. G. Cantley
Cell Confluence Regulates Hepatocyte Growth Factor-Stimulated Cell Morphogenesis in a {beta}-Catenin-Dependent Manner
Mol. Cell. Biol.,
December 15, 2006;
26(24):
9232 - 9243.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.-H. Teng, Y. Xie, S. Shin, F. Di Cello, M. Paul-Satyaseela, M. Cai, and K. S. Kim
Effects of ompA Deletion on Expression of Type 1 Fimbriae in Escherichia coli K1 Strain RS218 and on the Association of E. coli with Human Brain Microvascular Endothelial Cells.
Infect. Immun.,
October 1, 2006;
74(10):
5609 - 5616.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. S. Kristof, G. Pacheco-Rodriguez, B. Schremmer, and J. Moss
LY303511 (2-Piperazinyl-8-phenyl-4H-1-benzopyran-4-one) Acts via Phosphatidylinositol 3-Kinase-Independent Pathways to Inhibit Cell Proliferation via Mammalian Target of Rapamycin (mTOR)- and Non-mTOR-Dependent Mechanisms
J. Pharmacol. Exp. Ther.,
September 1, 2005;
314(3):
1134 - 1143.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. W. Poh and S. Pervaiz
LY294002 and LY303511 Sensitize Tumor Cells to Drug-Induced Apoptosis via Intracellular Hydrogen Peroxide Production Independent of the Phosphoinositide 3-Kinase-Akt Pathway
Cancer Res.,
July 15, 2005;
65(14):
6264 - 6274.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Sissons, K. S. Kim, M. Stins, S. Jayasekera, S. Alsam, and N. A. Khan
Acanthamoeba castellanii Induces Host Cell Death via a Phosphatidylinositol 3-Kinase-Dependent Mechanism
Infect. Immun.,
May 1, 2005;
73(5):
2704 - 2708.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Kierbel, A. Gassama-Diagne, K. Mostov, and J. N. Engel
The Phosphoinositol-3-Kinase-Protein Kinase B/Akt Pathway Is Critical for Pseudomonas aeruginosa Strain PAK Internalization
Mol. Biol. Cell,
May 1, 2005;
16(5):
2577 - 2585.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. J. Kim, J. W. Chung, and K. S. Kim
67-kDa Laminin Receptor Promotes Internalization of Cytotoxic Necrotizing Factor 1-expressing Escherichia coli K1 into Human Brain Microvascular Endothelial Cells
J. Biol. Chem.,
January 14, 2005;
280(2):
1360 - 1368.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. K. Sukumaran, G. McNamara, and N. V. Prasadarao
Escherichia coli K-1 Interaction with Human Brain Micro-vascular Endothelial Cells Triggers Phospholipase C-{gamma}1 Activation Downstream of Phosphatidylinositol 3-Kinase
J. Biol. Chem.,
November 14, 2003;
278(46):
45753 - 45762.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. K. Sukumaran, H. Shimada, and N. V. Prasadarao
Entry and Intracellular Replication of Escherichia coli K1 in Macrophages Require Expression of Outer Membrane Protein A
Infect. Immun.,
October 1, 2003;
71(10):
5951 - 5961.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Neff, M. Zeisel, V. Druet, K. Takeda, J.-P. Klein, J. Sibilia, and D. Wachsmann
ERK 1/2- and JNKs-dependent Synthesis of Interleukins 6 and 8 by Fibroblast-like Synoviocytes Stimulated with Protein I/II, a Modulin from Oral Streptococci, Requires Focal Adhesion Kinase
J. Biol. Chem.,
July 18, 2003;
278(30):
27721 - 27728.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. S. Rudrabhatla, S. K. Sukumaran, G. M. Bokoch, and N. V. Prasadarao
Modulation of Myosin Light-Chain Phosphorylation by p21-Activated Kinase 1 in Escherichia coli Invasion of Human Brain Microvascular Endothelial Cells
Infect. Immun.,
May 1, 2003;
71(5):
2787 - 2797.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. V. Prasadarao, P. K. Srivastava, R. S. Rudrabhatla, K. S. Kim, S.-h. Huang, and S. K. Sukumaran
Cloning and Expression of the Escherichia coli K1 Outer Membrane Protein A Receptor, a gp96 Homologue
Infect. Immun.,
April 1, 2003;
71(4):
1680 - 1688.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
S. K. Sukumaran, M. J. Quon, and N. V. Prasadarao
Escherichia coli K1 Internalization via Caveolae Requires Caveolin-1 and Protein Kinase Calpha Interaction in Human Brain Microvascular Endothelial Cells
J. Biol. Chem.,
December 20, 2002;
277(52):
50716 - 50724.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. A. Khan, Y. Wang, K. J. Kim, J. W. Chung, C. A. Wass, and K. S. Kim
Cytotoxic Necrotizing Factor-1 Contributes to Escherichia coli K1 Invasion of the Central Nervous System
J. Biol. Chem.,
May 3, 2002;
277(18):
15607 - 15612.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Shi, S. Barnes, M. Coca-Prados, and M. E. M. Kelly
Protein Tyrosine Kinase and Protein Phosphatase Signaling Pathways Regulate Volume-Sensitive Chloride Currents in a Nonpigmented Ciliary Epithelial Cell Line
Invest. Ophthalmol. Vis. Sci.,
May 1, 2002;
43(5):
1525 - 1532.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. K. Sukumaran and N. V. Prasadarao
Regulation of Protein Kinase C in Escherichia coli K1 Invasion of Human Brain Microvascular Endothelial Cells
J. Biol. Chem.,
March 29, 2002;
277(14):
12253 - 12262.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. S. Kim
Escherichia coli Translocation at the Blood-Brain Barrier
Infect. Immun.,
September 1, 2001;
69(9):
5217 - 5222.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. V. Chuenkova, F. B. Furnari, W. K. Cavenee, and M. A. Pereira
Trypanosoma cruzi trans-sialidase: A potent and specific survival factor for human Schwann cells by means of phosphatidylinositol 3-kinase/Akt signaling
PNAS,
July 24, 2001;
(2001)
161298398.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. V. Chuenkova, F. B. Furnari, W. K. Cavenee, and M. A. Pereira
Trypanosoma cruzi trans-sialidase: A potent and specific survival factor for human Schwann cells by means of phosphatidylinositol 3-kinase/Akt signaling
PNAS,
August 14, 2001;
98(17):
9936 - 9941.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|